University Of California San Francisco

Systemic lupus erythematosus is more severe among U.S. Asian populations compared with whites, with Filipino individuals in particular affected at “strikingly” young ages, according to findings published in Arthritis Care & Research.

Metastasis and prostate cancer-specific death appeared rare among men with low-risk and carefully selected intermediate-risk prostate cancer undergoing long-term active surveillance, according to study data published in Journal of Urology.

Omecamtiv mecarbil (Amgen/Cytokinetics/Servier) for reduction of HF events and death in HF with reduced ejection fraction.

The FDA approved margetuximab-cmkb for use in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer, according to a press release from the agent’s manufacturer.

Pembrolizumab improved response rates regardless of chemotherapy partner among patients with metastatic triple-negative breast cancer, according to KEYNOTE-355 trial results presented at the virtual San Antonio Breast Cancer Symposium.

The FDA today approved Gallium 68 PSMA-11 as the first drug for PET imaging of prostate-specific membrane antigen-positive lesions in men with prostate cancer, according a press release from the agency.

At least one-fifth of racial disparities in hypertension treatment may stem from racial inequities in treatment intensification, according to a study presented at the virtual American Heart Association Scientific Sessions.

Patients with hepatocellular carcinoma who live in rural regions or lower-income households had more advanced disease at diagnosis and higher disease-related mortality than other patients, according to study results published in Cancer.

While we know women are threefold more likely than men to receive an MS diagnosis and they are usually diagnosed during their childbearing years, data on the impact of pregnancy on MS outcomes remain less clear.

Omecamtiv mecarbil, a novel selective cardiac myosin activator, was associated with an 8% reduction in CV death or first HF events in patients with HF with reduced ejection fraction, according to results of the GALACTIC-HF trial.